ULGX Urologix, Inc. featured news, full reports, and detailed charts
Urologix, Inc. (ULGX) Wrap Up:
Urologix develops, manufactures, and markets non-surgical, catheter-based therapies that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a disease that affects more than 23 million men worldwide. We market our control units under the Targis,® Prostatron® and CoolWave® names and our procedure kits under the CTC™, Targis and Prostaprobe™ names. We are also in the process of developing our next generation catheter, CoolMax™, in which we are planning to combine durability with increased patient comfort. All systems utilize the Company’s Cooled ThermoTherapy technology, a targeted microwave energy combined with a unique cooling mechanism that protects healthy tissue and enhances patient comfort while providing safe, effective, lasting relief from the symptoms of BPH. Cooled ThermoTherapy can be performed without anesthesia or intravenous sedation and can be performed in a physician’s office or an outpatient clinic. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2007%2f09%2f20%2f0001193125-07-203879.html#FIS_BUSINESS"Urologix, Inc. (ULGX:NASDAQ)
Snapshot of Urologix, Inc. (ULGX)
|
OPEN
$0.96
|
PREVIOUS CLOSE
$1.01
|
|
|
DAY HIGH
$0.99
|
DAY LOW
$0.96
|
|
|
52 WEEK HIGH
08/5/09 - $1.31
|
52 WEEK LOW
03/4/09 - $0.21
|
|
|
MARKET CAP
14.2M
|
AVERAGE VOLUME 3 mo
28.7K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
14.5M
|
|
|
ULGX Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
ULGX Top Compensated Officers
Executives, Board Directors
Key developments for Urologix, Inc. (ULGX)
Urologix Inc. reported unaudited earnings results for the first quarter ended September 30, 2009. Revenue for the first quarter was $3.9 million, or 45% more than the $2.7 million reported in the same period of fiscal 2009. Revenue was 12% more than the $3.4 million reported in the fourth quarter of fiscal 2009. The increase in revenue over both the first quarter and fourth quarter of fiscal 2009 is due to increased sales in all distribution channels: Urologix mobile service, direct and third-party mobile services. Net loss for the first quarter was $677,000, or a loss of $0.05 per diluted share. This compares to a net loss of $1.3 million or $0.09 per diluted share for the first quarter of fiscal 2009, and a loss of $876 000 or $0.06 per diluted share in the fourth quarter of fiscal 2009. The company reported loss before income taxes of $681,000 compared to the loss before income tax of $1.240 million. The company reported operating loss of $681,000 compared to the operating loss of $1.286 million for the same period a year ago. The company reported that net cash used for operating activities of $1.013 million compared to the net cash used for operating activities of $1.818 million for the same period a year ago. The company announced purchase of property and equipment of $38,000 compared to the purchase of property and equipment of $16,000 for the same period a year ago.
Urologix, Inc. expected to Report Q2 2010 Results on January 25, 2010. This event was calculated by Capital IQ (Created on October 27, 2009).
Urologix, Inc., Q1 2010 Earnings Call, Oct 27 2009
ULGX Competitors
| Company | Last | Change |
| American Medical Systems Holdings Inc | $17.16 USD | -0.19 |
| ArthroCare Corp | $21.80 USD | -0.25 |
| Boston Scientific Corp | $8.09 USD | -0.12 |
| Medtronic Inc | $39.62 USD | +0.01 |
| Merck & Co Inc | $36.46 USD | +1.13 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | ULGX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 1.0x |
|
| Price/Book | 1.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.6x |
|
|
ULGX |
||
ULGX transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
